Luma Group
VC Fund
New York, United States
Luma Group is an investment firm focused on the intersection of technology-driven life sciences and healthcare companies.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 60%
Last updated:
For AI agents: llms.txt
Industries Luma Group invests in
Stages Luma Group invests in
Countries Luma Group invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $40M–$125M
- Series B
- $55M–$93M
Investment Focus
Industry
- Biotechnology 4 (80%)
- Health Care 3 (60%)
- Biopharma 2 (40%)
- Pharmaceutical 2 (40%)
- Analytics 1 (20%)
Stage
- Series A 2 (40%)
- Series B 1 (20%)
- Series C 1 (20%)
Country
- United States 3 (60%)
- Belgium 1 (20%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Themasap Khan
Co-Founder and Partner
|
Co-Founder and Partner | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Coultreon Biopharma
|
Coultreon Biopharma is developing best-in-class therapeutics that target clinically validated pathways in immunology and metabolic illnesses.Coultreon Biopharma employs extensive experience in disease biology, drug development, and translational science to identify the optimum treatment approach for addressing underlying illness biology withbest-in-class therapeutics. | $125M / Series A / Apr 28, 2026 | |
Aeovian Pharmaceuticals
|
Aeovian Pharmaceuticals develops and investigates targeted small molecule therapeutics aimed at restoring cellular metabolic quality control to address dysregulated growth and signaling linked to certain rare genetic and age-related conditions. The company’s pipeline centers on compounds that selectively modulate specific biological pathways,including inhibitors designed to influence disease processes associated with neurological dysfunction. Its lead development candidate is a central nervous system-penetrant selective inhibitor being evaluated in clinical trials for refractory seizures related to a genetic disorder, and additional compounds are in earlier stages of investigation for other disease areas. Aeovian Pharmaceuticals also maintains a portfolio of proprietary molecules that engage defined molecular targets to explore potential treatments beyond its program. | $55M / Series B / Dec 16, 2025 | |
Curve Biosciences
|
Curve Biosciences is a biotechnology company focused on enhancing chronic disease care through precision medicine. With a team led by experts such as Nathan Hunkapiller, PhD, as Chief Scientific Officer, and Chuba Oyolu, PhD, as Chief Technology Officer, the company is at the forefront of research and development in the biotech field. CurveBiosciences aims to leverage scientific advancements to provide targeted solutions for chronic diseases, emphasizing the importance of precision in treatment approaches. The company operates within the biotechnology industry and is dedicated to improving patient outcomes through innovative research. | $40M / Series A / Oct 29, 2025 | |
Character Biosciences
|
Biopharmaceutical research and development company that's an affiliate of Clover Health | $93M / Series B / Mar 25, 2025 | |
ArsenalBio
|
ArsenalBio is building a programmable cell therapy company to create highly effective and accessible immune cell therapies to impact outcomes for a much broader number of patients, initially those with cancer. Founded in 2019, ArsenalBio is focused on integrating technologies such as CRISPR-based genome engineering, scaled and high throughputtarget identification, synthetic biology, and machine learning to advance a new paradigm to discover and develop immune cell therapies. With its programmable and computationally driven approach, ArsenalBio aspires to evolve critical metrics of success for immune cell therapies, including enhanced and broader efficacy, increased patient safety, reduced provider costs and expanded market access. | $325M / Series C / Sep 04, 2024 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Luma Group invest in?
Luma Group invests primarily in Biotechnology, Health Care and Biopharma startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Luma Group's check size?
Luma Group typically joins rounds of $40M–$125M at Series A and $55M–$93M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Luma Group participates in.
How do I contact Luma Group?
Public channels for Luma Group include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Luma Group?
The team at Luma Group includes Themasap Khan (Co-Founder and Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
